« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 121, Issue 5
, Pages
1133-1139.e1
, May 2008
Acute respiratory health effects of air pollution on children with asthma in US inner cities
-
Box plots showing the distribution of the ambient air pollutant concentrations measured in all 7 communities during the 2-year period of the study. The bars indicate the 1st, 10th, 25th, 50th, 75th, 9
Box plots showing the distribution of the ambient air pollutant concentrations measured in all 7 communities during the 2-year period of the study. The bars indicate the 1st, 10th, 25th, 50th, 75th, 90th, and 99th percentiles of the measurements recorded. The red horizontal line near the top of some plots indicates the NAAQS for that pollution measure. Avg, Average; Max, maximum.
-
Estimated effect (95% CI) on pulmonary function of a 10th to 90th percentile increment in pollutant level in single-pollutant models among 937 inner-city children with asthma. The estimates shown areEstimated effect (95% CI) on pulmonary function of a 10th to 90th percentile increment in pollutant level in single-pollutant models among 937 inner-city children with asthma. The estimates shown are from models that included either a 1-day or 5-day average of pollutant concentration as the independent exposure variable. Adjusted for site, month, site-by-month interaction, temperature, and intervention group in mixed models. A, Percent predicted FEV1 as outcome variable. B, Percent predicted PEFR as outcome variable.
Supported by grants AI-39769, AI-39900, AI-39902, AI-39789, AI-39901, AI-39761, AI-39785, and AI-39776 from the National Institute of Allergy and Infectious Diseases and the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services; and by grant M01 RR00533 from the National Center for Research Resources, National Institutes of Health, Department of Health and Human Services; with partial support provided by the US Environmental Protection Agency through an interagency agreement with the National Institute of Allergy and Infectious Diseases. The manuscript has been subjected to agency review and approved for publication. The opinions expressed here do not necessarily reflect US Environmental Protection Agency policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.
Disclosure of potential conflict of interest: R. Gruchalla has received research support from Novartis. W. Morgan has consulting arrangements with the Cystic Fibrosis Foundation; has patent licensing arrangements with the Childhood Asthma Research and Education Network and the National Heart, Lung, and Blood Institute; has received research support from the Cystic Fibrosis Foundation and the National Institute of Allergy and Infectious Diseases; and is on the advisory board for Genentech. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)00407-7
doi: 10.1016/j.jaci.2008.02.020
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Allergy and Clinical Immunology
Volume 121, Issue 5
, Pages
1133-1139.e1
, May 2008
